$PRPO

SANDBERG RICHARD A sold $23K of PRPO (indirect holdings)

SANDBERG RICHARD A sold 900 indirectly-held shares of Precipio, Inc. (PRPO) at $25.02 on 2026-05-21.

Original reporting
SEC EDGAR · SANDBERG RICHARD A
Published May 26, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PRPO
Neutral
low confidence
Mentioned
$PRPO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRPONeutralLow
01

Why it matters

This is a disclosure of an open-market sale by a director; it can slightly influence sentiment but does not provide new information on earnings, trials, deals, or regulation.

02

Market read

Traders may monitor for clustering of insider sales, but this single, small transaction is unlikely to be a standalone driver.

03

What to watch

No 10b5-1 plan is stated; however, absence of that detail in the snippet does not confirm opportunistic trading or future selling.

Relevance 6/10Timing: Immediate (new SEC Form 4 disclosure dated May 26, covering a May 21 sale).

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Precipio, Inc. (PRPO).

Company-level read

Ticker impact

$PRPONeutralLow confidence
Context

Precipio director Richard A Sandberg sold 900 shares in an open-market transaction disclosed via SEC Form 4 on May 21, 2026.

Expected impact

Likely limited near-term impact; any reaction may be muted unless follow-on selling or broader negative catalysts emerge.

Evidence & confidence

The filing is an insider transaction without accompanying company fundamentals, and the disclosed sale size/value (~$22.5K) is unlikely to drive price by itself.

Market effects

Minimal sector read-through; this is company-specific insider activity with no stated operational/regulatory trigger.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing rather than a bearish view, especially since holdings remain at 3,000 shares post-sale.

Key entities

  • Precipio, Inc.

    Company whose director disclosed an open-market sale of 900 shares via SEC Form 4.

  • Richard A. Sandberg

    Director who sold 900 shares at ~$25.0193/share; holdings after transaction: 3,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PRPOMedAI 8/10

Precipio, Inc. Q2 2026 Earnings: Revenue Beats $7.02 Million Record

Precipio (NASDAQ: PRPO) reported Q2 2026 GAAP EPS of -$0.12 and a GAAP net loss of $0.219 million, alongside record net sales of $7.02 million, up about 24% year over year. Revenue beat the cited consensus $1.68 million. Product revenue rose to $0.906 million and adjusted EBITDA was $0.4 million. Cash at quarter-end was $3.08 million.

$PRPOMed

Precipio, Inc. (PRPO): Results of Operations and Financial Condition

Precipio, Inc. (PRPO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PR

$PRPOMed

Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200

Precipio Inc. (NASDAQ:PRPO) shares fell below their 200-day moving average during Wednesday trading, trading as low as $23.44 and last at $23.55. The 200-day average is $25.08. The article cites recent analyst changes, including a downgrade to “hold” by Wall Street Zen and “sell” ratings from Weiss. Precipio reported May 14 quarterly EPS of ($0.81) on $6.71M revenue.

$SIONMed

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).